SEAL Therapeutics is developing its proprietary SEAL technology as a potential gene therapy for laminin-α2 deficient congenital muscular dystrophy (LAMA2 MD), a severe and progressive neuromuscular disease affecting children from birth. SEAL Therapeutics aims to team-up with and support a qualified pharma partner with experience in advanced gene therapy technologies for clinical development to ultimately make this innovative treatment approach available to patients.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Spitalstrasse 41, Biozentrum,c/o Prof. Markus A Rüegg,switzerland
- Industry
- Biotechnology
- Website
- http://www.sealtherapeutics.com
- Keywords
- Basel.
- HQ
- Basel
Seal Therapeutics Ag Questions
Seal Therapeutics Ag's website is http://www.sealtherapeutics.com
Seal Therapeutics Ag's LinkedIn profile is https://ch.linkedin.com/company/seal-therapeutics-ag
Seal Therapeutics Ag has
3 employees.
View email and phone details for 3
employees at Seal Therapeutics Ag.
Seal Therapeutics Ag's industry is
Biotechnology
Seal Therapeutics Ag's top competitors are
Leucid Bio,
Viopas Venture Consulting Gmbh,
Cimeio Therapeutics,
Tolremo Therapeutics,
Neurosterix,
Alentis Therapeutics,
Cellestia Biotech,
Anaveon Ag,
Versameb Ag,
Amyra Biotech Ag.
Seal Therapeutics Ag's categories are Biotechnology
Seal Therapeutics Ag's founding year is 2021
